Entering text into the input field will update the search result below
Create free account
Search for Symbols, analysts, keywords
Log in
Analysis
All Analysis
AI Tech
Basic Materials
Biotech
Bonds
Closed End Funds
Commodities
Communication Services
Consumer
Consumer Staples
Cryptocurrency
Dividend Ideas
Dividend Quick Picks
Dividend Strategy
Dividends
Economy
Editors' Picks
Energy
ETF Analysis
ETFs and Funds
Financial Advisor
Financials
Fixed Income
Forex
Gold & Precious Metals
Growth
Healthcare
Industrial
Interest Rates
Investing Strategy
IPOs
Long Ideas
Magnificent 7
Market Outlook
Micro-Caps
Mutual Funds
Portfolio Strategy
Quick Picks & Lists
Real Estate
REITs
Retirement
Small-Caps
Stock Ideas
Tech
Utilities
Value
Weight Loss
Micro-Cap Stocks
Planet 13 Is The Best American Cannabis Stock
MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
A Strong Buy - Actinium Pharmaceuticals Promising AML Treatment With Targeted Radiotherapies
Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround
Jewett-Cameron Trading Company Is A Hold For Now
Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box
SKYX Platforms: Steady Growth While Waiting For A Potential Home Run
Luna: An Update On This Great Story That Turned Into A Potential Death Spiral
New Buy, Medicenna: Superkine Platform In Oncology
Expensify: A Busted IPO To An Undervalued SaaS Micro-Cap
TAG Oil: Valuation Missing 75% Of Assets (And Is Still Cheap)
Puma Biotechnology: A Story In Flux Heading Into Mid-2024
BioAtla: A Buried ADC Concern Gets Some New Life In 2024
Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects
Immutep: Realizing The Expected Catalysts, With More To Come
Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative Diseases
Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts
GlycoMimetics: Is No News Bad News?
Annovis Bio: Searching For Efficacy In Alzheimer's Disease
X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside
Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom
Uncovering The Hidden Value In American Lithium
PDS Biotechnology: Entering A Holding Pattern While Cash Remains A Concern (Rating Downgrade)
Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy
Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression
Inovio Pharmaceuticals: Neutral On INO-3107 Amidst Stock Dilution And High Valuation
Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Inovio Pharmaceuticals: The Dilution Continues
InterCure: Bargain Israel Cannabis Play
Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)
INmune Bio: An Opportunity In The Freefall (Rating Upgrade)
Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
Barnes & Noble Education: Shares Crater After Proposed Recapitalization - Hold
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout
Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
1
2
Next
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.